LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

January 14
Last Trade: 2.87 -0.06 -2.05

PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal SOUTH SAN FRANCISCO, Calif. / Jan 14, 2025 / Business Wire / Vistagen...Read more


Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

January 14
Last Trade: 0.94 0.63 203.56

CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is...Read more


Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

January 14
Last Trade: 2.49 -0.13 -4.96

Interim data from Cohort 4 expected Q1 2025  MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for...Read more


AstraZeneca: Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced...

January 13
Last Trade: 65.01 -0.73 -1.11

Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials Approval would mark the first for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in lung cancer WILMINGTON, Del. / Jan 13, 2025 / Business Wire / AstraZeneca and Daiichi...Read more


Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma

January 13
Last Trade: 36.03 -0.53 -1.45

The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2 The test helps differentiate a B-cell cancer from a normal, reactive immune...Read more


Biogen: FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the...

January 13
Last Trade: 146.96 -3.22 -2.14

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...Read more


Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Finch Therapeutics 8.80 488.89 $10.60
Agilent Technologies 5.93 4.36 $142.03
argenx 4.99 0.74 $675.39
Acadia Healthcare 4.41 11.12 $44.06
Sarepta Therapeutics 4.19 3.54 $122.62
iRhythm Technologies 3.94 4.17 $98.53
Accolade 3.41 98.98 $6.85
Medtronic 3.31 4.05 $85.11
Praxis Precision Medicines 2.95 4.61 $66.97
DaVita 2.93 1.87 $159.99
Evaxion Biotech 2.92 343.53 $3.77
Sonendo 2.77 1,204.35 $3.00
Ascendis Pharma 2.76 2.06 $136.80
BioNTech 2.75 2.42 $116.49
SANUWAVE Health 2.75 10.48 $29.00
TG Therapeutics 2.74 9.90 $30.42
Veradigm 2.69 39.50 $9.50
Integer 2.50 1.85 $137.65

Highest Volume

 
CompanyVolumeLast Trade
Eterna Therapeutics 583,669,367 $0.94
P3 Health Partners 169,089,826 $0.23
Tonix Pharmaceuticals 59,986,556 $0.24
Quantum-Si 18,231,376 $2.04
Soligenix 15,112,401 $2.69
Senseonics 11,613,509 $0.75
CNS Pharmaceuticals 11,514,666 $0.11
Walgreens Boots Alliance 11,269,257 $12.28
Aditxt 11,173,850 $0.14
Mustang Bio 10,239,522 $0.14
Conduit Pharmaceuticals 9,328,147 $0.10
Intra-Cellular Therapies 8,958,700 $127.06
Mobile-health Network Solutions 8,161,396 $0.37
Phio Pharmaceuticals 7,775,201 $3.59
Eyenovia 6,775,784 $0.09
Iovance Biotherapeutics 6,686,869 $6.19
Azitra 6,646,191 $0.49
Mersana Therapeutics 6,079,050 $0.64
Geron 6,032,031 $3.04
  • Upcoming FDA Catalysts

    • Axsome Therapeutics (NASDAQ: AXSM) PDUFA Date

      January 25, 2025
    • Vertex Pharmaceuticals (NASDAQ: VRTX) PDUFA Date

      January 30, 2025
    • Supernus Pharmaceuticals (NASDAQ: SUPN) PDUFA Date

      February 1, 2025
    • Merus (NASDAQ: MRUS) PDUFA Date

      February 4, 2025
    • Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

      February 28, 2025
    • Eton Pharmaceuticals (NASDAQ: ETON) PDUFA Date

      February 28, 2025

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Assertio

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: